NYSE · Financial Statements

ResMed Inc. (RMD) Revenue, Earnings & Financial Statements

$237.85 NYSE: RMD Market Cap $33.46B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

ResMed Inc. most recently reported annual revenue of $5.7B, net profit of $1.5B. Revenue grew at an average annual rate of 12.1% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

ResMed Inc.: Revenue rose from $2.1B in 2017 to $5.7B in 2026, a change of +173.5% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 20.6% to 33.8%, a shift of +13.2 percentage points; the most recent year shows net profit of $1.5B.

Income Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Revenue$2.1B$2.3B$2.6B$3.0B$3.2B$3.6B$4.2B$4.7B$5.1B$5.7B
Operating Expenses$1.6B$1.8B$2.0B$2.1B$2.3B$2.6B$3.1B$3.4B$3.5B$3.7B
Operating Profit$426.0M$542.0M$579.0M$810.0M$904.0M$1.0B$1.1B$1.3B$1.7B$1.9B
Operating Margin20.6%23.1%22.2%27.4%28.3%28.0%26.8%28.2%32.8%33.8%
Other Income−$7.0M−$21.0M−$60.0M−$77.0M−$20.0M−$40.0M−$30.0M−$55.0M−$8.0M$11.0M
Interest$28.0M$28.0M$36.0M$40.0M$24.0M$22.0M$47.0M$46.0M$13.0M$0
Depreciation$112.0M$120.0M$151.0M$181.0M$192.0M$194.0M$198.0M$216.0M$236.0M$244.0M
Profit Before Tax$419.0M$521.0M$519.0M$733.0M$884.0M$960.0M$1.1B$1.3B$1.7B$1.9B
Tax rate (%)18.3%39.5%22.0%15.2%46.3%18.9%18.5%19.3%16.5%20.6%
Net Profit$342.0M$316.0M$405.0M$622.0M$475.0M$779.0M$898.0M$1.0B$1.4B$1.5B
EPS$2.40$2.19$2.80$4.27$3.24$5.30$6.09$6.92$9.51$10.40

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$1.2B$1.2B$1.2B$1.2B$1.3B$1.3B$1.3B$1.3B$1.4B$1.4B$1.5B$1.4B
Operating Expenses$888.0M$822.0M$842.0M$837.0M$865.0M$865.0M$893.0M$889.0M$925.0M$932.0M$1.0B$962.0M
Operating Profit$275.0M$375.0M$381.0M$387.0M$417.0M$426.0M$455.0M$447.0M$498.0M$500.0M$449.0M$453.0M
Operating Margin23.7%31.3%31.2%31.6%32.5%33.0%33.7%33.4%35.0%34.9%30.7%32.0%
Interest$14.0M$14.0M$10.0M$6.0M$5.0M$3.0M$0$9.0M$8.0M$12.0M$0$5.0M
Profit Before Tax$259.0M$375.0M$358.0M$383.0M$418.0M$418.0M$458.0M$447.0M$496.0M$502.0M$474.0M$539.0M
Tax rate (%)19.5%20.0%18.3%18.8%17.6%12.6%17.1%22.0%20.9%20.6%19.1%22.4%
Net Profit$209.0M$300.0M$292.0M$311.0M$345.0M$365.0M$380.0M$349.0M$393.0M$399.0M$383.0M$418.0M
EPS$1.42$2.04$1.98$2.11$2.34$2.48$2.58$2.37$2.68$2.71$2.64$2.92

Over the 10 years reported for ResMed Inc., borrowings decreased from $1.1B in 2017 to $826.0M in 2026, cash stood at $1.5B in the latest year, shareholders' equity was $1.0M, current assets covered current liabilities 3.10 times.

Balance Sheet — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Total Assets$3.5B$3.1B$4.1B$4.6B$4.7B$5.1B$6.8B$6.9B$8.2B$9.0B
Current Assets$1.6B$1.1B$1.1B$1.5B$1.6B$1.9B$2.4B$2.4B$3.5B$4.3B
Cash$822.0M$189.0M$147.0M$463.0M$295.0M$274.0M$228.0M$238.0M$1.2B$1.5B
Inventory$268.0M$269.0M$350.0M$417.0M$457.0M$744.0M$998.0M$822.0M$928.0M$946.0M
Receivables$451.0M$484.0M$528.0M$475.0M$625.0M$576.0M$705.0M$837.0M$991.0M$1.0B
Fixed Assets$394.0M$387.0M$387.0M$536.0M$592.0M$630.0M$666.0M$699.0M$718.0M$735.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$38.0M$41.0M$57.0M$51.0M$75.0M$67.0M$157.0M$170.0M$85.0M$0
Other Assets$1.1B$1.1B$1.9B$1.9B$1.9B$1.9B$2.8B$2.8B$3.0B$3.4B
Total Liabilities$1.5B$1.0B$2.0B$2.1B$1.8B$1.7B$2.6B$2.0B$2.2B$2.4B
Current Liabilities$360.0M$511.0M$556.0M$603.0M$912.0M$689.0M$759.0M$911.0M$1.0B$1.4B
Borrowings$1.1B$281.0M$1.3B$1.3B$794.0M$918.0M$1.6B$874.0M$852.0M$826.0M
Other Liabilities$430.0M$723.0M$765.0M$791.0M$1.0B$818.0M$1.0B$1.1B$1.4B$1.6B
Equity$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Reserves$2.0B$2.1B$2.1B$2.5B$2.9B$3.4B$4.1B$4.9B$6.0B$6.6B

For ResMed Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $1.6B; free cash flow was positive in 10 of 10 years; financing activities used $722.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Operating Cash Flow$414.0M$505.0M$459.0M$802.0M$737.0M$351.0M$693.0M$1.4B$1.8B$1.8B
Investing Cash Flow−$150.0M−$173.0M−$1.2B−$286.0M−$275.0M−$386.0M−$1.3B−$385.0M−$290.0M−$701.0M
Financing Cash Flow−$20.0M−$16.0M−$52.0M−$46.0M−$54.0M−$52.0M−$33.0M−$160.0M−$330.0M−$722.0M
Net Cash Flow$91.0M−$633.0M−$42.0M$316.0M−$168.0M−$22.0M−$46.0M$10.0M$971.0M$260.0M
Free Cash Flow$343.0M$434.0M$382.0M$696.0M$620.0M$195.0M$559.0M$1.3B$1.7B$1.6B

Valuation & Return Ratios

MetricValue
PEG Ratio1.19
EV / EBITDA15.29
FCF Yield4.92%
Quick Ratio2.42
Interest Coverage75.81
Return 1Y-3.95%
Return 3Y67.40%
Return 5Y-2.20%

ResMed Inc. (RMD) financials — frequently asked questions

What is ResMed Inc.'s annual revenue?

ResMed Inc. (RMD) reported annual revenue of $5.7B in its most recent fiscal year.

What is ResMed Inc.'s net profit?

ResMed Inc. (RMD) reported net profit of $1.5B in its most recent fiscal year.

What is RMD EV/EBITDA?

ResMed Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 15.29.

Revenue and earnings of other Medical - Devices stocks

ABT revenue $44.3BISRG revenue $10.1BMDT revenue $36.4BSYK revenue $25.1BBSX revenue $20.1BEW revenue $6.1BDXCM revenue $4.7BPHG revenue $17.8BZBH revenue $8.2BGKOS revenue $507.0MAll Medical - Devices stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
RMD Overview RMD Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.